Kura Oncology, Inc.KURANASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P13
Within normal range
vs 5Y Ago
-0.9x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -5.15% |
| Q3 2025 | 8.16% |
| Q2 2025 | 12.17% |
| Q1 2025 | 7.09% |
| Q4 2024 | 25.33% |
| Q3 2024 | 4.98% |
| Q2 2024 | 9.54% |
| Q1 2024 | 11.48% |
| Q4 2023 | 10.93% |
| Q3 2023 | 4.07% |
| Q2 2023 | 11.87% |
| Q1 2023 | 11.13% |
| Q4 2022 | -9.23% |
| Q3 2022 | 2.95% |
| Q2 2022 | 15.99% |
| Q1 2022 | -0.21% |
| Q4 2021 | -6.31% |
| Q3 2021 | 6.14% |
| Q2 2021 | 3.69% |
| Q1 2021 | 15.98% |
| Q4 2020 | 5.56% |
| Q3 2020 | 21.20% |
| Q2 2020 | 8.92% |
| Q1 2020 | -6.60% |
| Q4 2019 | 7.37% |
| Q3 2019 | 9.62% |
| Q2 2019 | 10.19% |
| Q1 2019 | -14.08% |
| Q4 2018 | 3.63% |
| Q3 2018 | 1.61% |
| Q2 2018 | -0.78% |
| Q1 2018 | 42.46% |
| Q4 2017 | 13.68% |
| Q3 2017 | 26.36% |
| Q2 2017 | 2.52% |
| Q1 2017 | 0.18% |
| Q4 2016 | 3.52% |
| Q3 2016 | 7.70% |
| Q2 2016 | 6.17% |
| Q1 2016 | -9.07% |